Related Experiment Videos
Glaucoma medications, glaucoma therapy, and the evolving paradigm
1Department of Veterans Affairs, Optometry Section, Brooklyn, New York, USA.
Journal of the American Optometric Association
|April 29, 1998
Summary
Modern open-angle glaucoma treatment has evolved significantly since the 1980s, incorporating new medications and procedures. Newer therapies offer improved efficacy and safety profiles for reducing intraocular pressure (IOP).
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Glaucoma treatment is dynamic, with significant evolution in therapeutic approaches since the 1980s.
- Topical beta-blockers remain a primary treatment for open-angle glaucoma.
- Newer medications and modalities supplement traditional therapies.
Purpose of the Study:
- To compare current open-angle glaucoma treatment methods with those from the 1980s.
- To highlight advancements in glaucoma pharmacotherapy and surgical interventions.
Main Methods:
- Review of contemporary and historical treatment strategies for open-angle glaucoma.
- Evaluation of newly available medications and their efficacy and safety profiles.
- Assessment of procedures such as argon laser trabeculoplasty (ALT).
Main Results:
- Topical carbonic anhydrase inhibitors (CAIs) offer efficacy similar to oral forms but with fewer systemic side effects.
- Brimonidine (topical alpha2-adrenergic agonist) and latanoprost (topical prostaglandin) improve intraocular pressure (IOP) reduction with better therapeutic indices.
- Argon laser trabeculoplasty (ALT) is a safe and effective method for IOP reduction.
Conclusions:
- Treatment paradigms for open-angle glaucoma are continuously evolving.
- Ongoing research into existing and new anti-glaucoma medications will shape future therapeutic strategies.